Symbol | Exchange | Currency |
|---|
Ahead of a business update scheduled at the J.P. Morgan Healthcare Conference next week, Mersana Therapeutics (MRSN) shared the anticipated timeline for 2022 milestones in the...
UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022UP-NEXT, a Phase 3 trial of UpRi monotherapy...
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a...
For Immediate ReleaseChicago, IL – July 1, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
1. AltimmuneAltimmune (NASDAQ:ALT) popped, exploded in May, going from about 2.90 all the way up to 10, and change, quadrupling, pulled back to the Fibonacci retracement, formed...
Apache Corporation (NYSE:APA) in the oil sector is still hanging in there. On Thursday, it popped 33 cents, or 2.38%, to 14.22,...
Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 162.41 | 166.33 | 162.30 | -2.10 | -1.28% | 121.54M | NASDAQ | |||
| 2,607.03 | 2,697.31 | 2,601.73 | -59.12 | -2.22% | 2.76M | NASDAQ | |||
| 303.17 | 318.31 | 303.04 | -13.39 | -4.23% | 28.31M | NASDAQ | |||
| 172.65 | 176.02 | 172.56 | -0.92 | -0.53% | 3.47M | NYSE | |||
| 499.91 | 513.86 | 499.27 | -10.94 | -2.14% | 4.19M | NASDAQ | |||
| 52.04 | 53.13 | 51.95 | 0.00 | 0.00% | 46.08M | NASDAQ | |||
| 2,852.86 | 3,018.00 | 2,841.41 | -180.49 | -5.95% | 8.09M | NASDAQ | |||
| 20.08 | 20.35 | 20.00 | -0.52 | -2.52% | 53.70K | OTC Markets | |||
| 14.53 | 14.77 | 14.51 | -0.11 | -0.75% | 11.20M | NASDAQ | |||
| 89.50 | 91.51 | 88.36 | -0.33 | -0.37% | 180.17K | NYSE | |||
| 19.33 | 19.91 | 19.23 | -0.70 | -3.49% | 8.72M | NYSE | |||
| 943.90 | 1,004.55 | 940.50 | -52.37 | -5.26% | 33.96M | NASDAQ | |||
| 397.50 | 409.15 | 379.99 | -110.75 | -21.79% | 58.65M | NASDAQ | |||
| 233.74 | 248.23 | 232.63 | -7.76 | -3.21% | 71.22M | NASDAQ | |||
| 145.08 | 147.51 | 144.27 | -2.58 | -1.75% | 20.55M | NYSE |